AAD

Patient Care Online provides primary care physicians with essential insights from the 2025 American Academy of Dermatology (AAD) Annual Meeting. Access expert guidance, clinical updates, and actionable content on the latest advancements in dermatologic care—all tailored to enhance your practice and patient outcomes.

Conference Highlights
Expert Interviews
Featured
Emergence of Trichophyton Indotineae: A Call for Culture-Driven Antifungal Therapy
Elizabeth Swanson, MD, FAAD
Sydney Jennings
March 17 2025
Daniel Butler, MD, a Leader in Geriatric Dermatology, Says Focus on the Overlap in the Etiology of Itch in Older Adults
Daniel Butler, MD
Grace Halsey
March 17 2025
Rethinking Shingles in Children: Expert Insights for Primary Care
Elizabeth Swanson, MD, FAAD
Sydney Jennings
March 15 2025
Measles Resurgence and Vaccine Efficacy: A Conversation with Elizabeth Swanson, MD
Elizabeth Swanson, MD, FAAD
Sydney Jennings
March 14 2025
Upadacitinib Demonstrates Superior Regional, Overall Efficacy vs Dupilumab in Atopic Dermatitis: Level Up Phase 3b/4 Trial Findings
Grace Halsey
March 14 2025
Hand, Foot, and Mouth Disease Update: A Conversation with Elizabeth Swanson, MD
Elizabeth Swanson, MD, FAAD
Sydney Jennings
March 13 2025
JiaDe Yu, MD: When to Refer Pediatric Patients with Suspected Contact Dermatitis
JiaDe Yu, MD
Sydney Jennings
March 13 2025
Advances in Understanding of Itch: A Conversation with Brian S Kim, MD, MTR, at the 2025 AAD Meeting
Brian S. Kim, MD
Grace Halsey
March 12 2025
Atopic Dermatitis of Childhood Onset Significantly Impacts "Life Trajectory" According to Scars of Life Survey
Grace Halsey
March 12 2025
Advances in Dermatology Therapeutics: Key Insights from AAD 2025
Sydney Jennings
March 11 2025
JiaDe Yu, MD: Key Signs of Allergic Contact Dermatitis in Children
JiaDe Yu, MD
Sydney Jennings
March 11 2025
Elizabeth Swanson, MD: When HSV Causes Big Dermatologic Problems
Elizabeth Swanson, MD, FAAD
Sydney Jennings
March 10 2025
For Atopic Dermatitis, "The Treatment Drought is Over," Says Expert Dermatologist Emma Guttman, MD, PhD
Grace Halsey
March 10 2025
Delgocitinib Data Reveal "Super Responders" in CHE During AAD 2025 Late Breaker
Grace Halsey
March 10 2025
Recognizing Allergic Contact Dermatitis in Children: Expert Pearls at AAD 2025
JiaDe Yu, MD
Sydney Jennings
March 10 2025
Brian S. Kim, MD: Why Primary Care Clinicians Should Prescribe New Treatments for Atopic Dermatitis
Brian S. Kim, MD
Grace Halsey
March 10 2025
Zabalafin Hydrogel Shows Efficacy in Atopic Dermatitis, Including Cases with Bacterial Infection
Patient Care Editorial Staff
March 10 2025
The Link Between Itch and Aging, with Daniel Butler, MD
Daniel Butler, MD
Grace Halsey
March 10 2025
The Complexities of Treating Rosacea, with Benjamin Ungar, MD
Benjamin Ungar, MD
Sydney Jennings
March 10 2025
Breakthroughs in Atopic Dermatitis with Linda Stein Gold, MD: Primary Viewpoints Podcast
Linda Stein Gold, MD
Sydney Jennings
March 9 2025
Daniel Butler, MD: Pearls for Primary Care When Treating and Referring Older Adults for Chronic Itch
Daniel Butler, MD
Grace Halsey
March 9 2025
Rocatinlimab, an OX40 Inhibitor, Achieves Positive Results in Atopic Dermatitis Treatment: ROCKET-Horizon Topline Findings
Grace Halsey
March 9 2025
Atopic Dermatitis Breakthrough: Linda Stein Gold, MD, on Tapinarof's Treatment-Free Benefits
Sydney Jennings
March 9 2025
Benjmain Ungar, MD: Addressing the Immunological Causes of Seborrheic Dermatitis
Benjamin Ungar, MD
Sydney Jennings
March 9 2025
Dupilumab Demonstrates Superior Long-Term Persistence Over Upadacitinib and Tralokinumab in Atopic Dermatitis
Grace Halsey
March 9 2025
Atopic Dermatitis: Investigational Anti-OX40L Antibody Shows Sustained Itch Relief, Even After Discontinuation
Sydney Jennings
March 8 2025
Atopic Dermatitis: It’s Not the Food, I Promise You
Peter A Lio, MD
Grace Halsey
March 8 2025
Ruxolitinib Cream 1.5% Demonstrates Efficacy in Prurigo Nodularis: Phase 3 Findings
Patient Care Editorial Staff
March 8 2025
Rocatinlimab Shows Significant Efficacy in Moderate to Severe Atopic Dermatitis: Phase 3 IGNITE Trial Results
Grace Halsey
March 8 2025
Icotrokinra Shows Promise for Moderate-to-Severe Plaque Psoriasis in Phase 3 Trials
Patient Care Editorial Staff
March 8 2025
© 2025 MJH Life Sciences

All rights reserved.